GENE ONLINE|News &
Opinion
Blog

Rare Disease
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
2022-01-17
Takeda Collaborates with Immusoft to Advance Treatments in Rare Metabolic Diseases
2022-01-14
Applied Therapeutics’ Galactosemia Program Stumbles Again after FDA Requests for More Data
2022-01-04
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Brukinsa Receives EU Approval for the Treatment of Rare Lymphoma
2021-11-27
FDA Approves Aadi Bioscience’s First Product to Treat Rare Cancer
2021-11-23
FDA Approves First Interferon Therapy for Rare Blood Cancer
2021-11-15
Big Pharma and Non-Profits Join NIH, FDA in New Rare Diseases Drive
2021-10-28
Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate
2021-10-22
FDA Greenlights First and Only Treatment for Cholestatic Pruritus with ALGS
2021-10-04
Merck Acquires Acceleron for $11.5 Billion, Gaining Access to a Phase 3 Cardiovascular Asset
2021-09-30
AstraZeneca Acquires Caelum in $500m Deal to Strengthen Rare Diseases Division
2021-09-30
Cancer Fears Puts BioMarin’s Phearless Study on Hold
2021-09-07
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
2021-09-06
Serious Adverse Event in Study Participant Marks Latest Roadblock for Astellas’ Gene Therapy Trial
2021-09-03
1 2 3
LATEST
Biotech Showcase 2022: Healing the Psyche with Psychedelia
2022-01-17
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
2022-01-17
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
Shanghai’s Everest Medicines Licenses Covid-19 Oral Antivirals from Singapore’s National Drug Discovery Platform
2022-01-17
Digital Health Programme to Connect British and Taiwanese Leaders
2022-01-17
Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults
2022-01-16
Concerns Remain as Kintor Pharma’s Proxalutamide Shows Unbelievably High Efficacy Against Covid-19 Infections in Phase 3 Trials
2022-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!